Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Randomised, Double-blind, Active and Placebo-controlled, 6-week Trial to Investigate the Efficacy and Safety of a Starting (and Fixed) Dose 0.25 mg Pramipexole (Mirapex®) in Patients With Idiopathic Restless Legs Syndrome

NCT00375284 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00375284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00375284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Randomised, Double-blind, Active and Placebo-controlled, 6-week Trial to Investigate the Efficacy and Safety of a Starting (and Fixed) Dose 0.25 mg Pramipexole (Mirapex®) in Patients With Idiopathic Restless Legs Syndrome
Lead sponsor
Boehringer Ingelheim
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2006
Completion date
Not reported
Enrollment
404 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

restless legs syndrome